AAS
PTGX icon

Ameritas Advisory Services’s Protagonist Therapeutics PTGX Stock Holding History

Ameritas Advisory Services’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-334
Closed -$35.2K – 2086
2026
Q1 		$35.2K Buy
+334
New +$29.6K ﹤0.01% 953

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Ameritas Advisory Services's PTGX Position: Q2 2026 in Review

Ameritas Advisory Services sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 334 shares — an estimated $35.2K sold.

Ameritas Advisory Services first reported a position in PTGX in Q1 2026 and held it in 1 quarter. The position peaked at $35.2K in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Ameritas Advisory Services reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ameritas Advisory Services sold 334 Protagonist Therapeutics shares in Q2 2026, an estimated $35.2K.
  • Ameritas Advisory Services first reported a position in Protagonist Therapeutics in Q1 2026 and held it in 1 quarter.
  • Ameritas Advisory Services's Protagonist Therapeutics position peaked at $35.2K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.